Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Pathologic Complete Response × pyrotinib × 1 year × Clear all

Sponsor

Conditions

Breast Neoplasms 9 HER2-positive Breast Cancer 4 Salivary Gland Neoplasms 1 Non-squamous NSCLC 1 Non Small Cell Lung 1 Locally Advanced Breast Cancer 1 HER2-positive Early Breast Cancer 1 HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane 1 HER2 Positive Breast Cancer 1 Carcinoma, Non-Small-Cell Lung 1 Breast Cancer Invasive 1 Breast Cancer Female 1 Advanced Digestive System Tumor 1 Advanced Breast Cancer 1

Interventions

Carboplatin 4 pembrolizumab 3 Paclitaxel 3 Capecitabine 3 Azacitidine 3 venetoclax 2 pertuzumab 2 olaparib 2 durvalumab 2 Trastuzumab 2 Standard of Care 2 Oxaliplatin 2 Observation 2 Irinotecan 2 Immunotherapy 2 Immune Checkpoint Inhibitors 2 Chemoradiotherapy 2 zanidatamab 1 veliparib 1 tucatinib 1 trilaciclib 1 trebananib 1 trastuzumab duocarmazine 1 tislelizumab 1 tegafur-gimeracil-oteracil 1 taxane 1 talazoparib 1 tagraxofusp 1 sarilumab 1 sargramostim 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡